MC4 receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Liu Wenhui (simplified Chinese: 刘文辉; traditional Chinese: 劉文輝; pinyin: Liú Wénhuī; Wade–Giles: Liu Wen-hui; 10 January 1895 – 24 June 1976) was a Chinese general and warlord of Sichuan and Xikang provinces (Sichuan clique). At the beginning of his career, he was aligned with the Kuomintang (KMT), commanding the Sichuan-Xikang Defence Force from 1927 to 1929. In 1929, he became Sichuan governor before being ousted by a coalition of warlords in 1933; from there, he controlled the western part of Sichuan province, then known as Xikang, ruling the area as a personal fiefdom. He maintained his autonomy from the Nationalist government and pursued development programs in the province, which he funded through the trade of opium and by maintaining cordial relations with Chiang Kai-shek during the Second Sino-Japanese War. In 1949 he defected to the Communist forces of Mao Zedong, and went on to hold high office in the new People's Republic of China, serving as Minister of Forestry (1959–1967), member of the National People's Congress, member of the National Committee of the Chinese People's Political Consultative Conference, and member of the Central Committee of the Revolutionary Committee of the Chinese Kuomintang.
Certain functions necessary to the trial, such as monitoring and lab work, may be managed by an outsourced partner, such as a contract research organization or a central laboratory. Only 10 percent of all drugs started in human clinical trials become approved drugs. Data collection is a key activity within clinical trials and digital data collection tools can assist greatly in this effort.
==== United States ==== Pentazocine was originally unclassified under the Controlled Substances Act in the United States. A petition was filed with the US Drug Enforcement Administration (DEA) on October 1, 1971, to shift it to Schedule III. The petition was filed by Joseph L. Fink III, a pharmacist and law student at Georgetown University Law Center as part of the course Lawyering in the Public Interest. That petition was accepted for review on November 10, 1971. The DEA published a Final Rule transferring it to Schedule IV on January 10, 1979, with an effective date of February 9, 1979. Pentazocine is still classified in Schedule IV under the Controlled Substances Act in the United States, even with the addition of naloxone. Some states classify it in Schedule II, such as Illinois and South Carolina (injectable form only), or Schedule III such as Kentucky.) Internationally, pentazocine is a Schedule III drug under the Convention on Psychotropic Substances, except in Canada where it is Schedule I under the federal Controlled Drugs and Substances Act. Pentazocine has a DEA ACSCN of 9720; being a Schedule IV substance, the DEA does not assign an annual manufacturing quota for pentazocine for the United States.
Sources: en.wikipedia.org
The outermost layer of the gastrointestinal tract consists of several layers of connective tissue. Intraperitoneal parts of the GI tract are covered with serosa. These include most of the stomach, first part of the duodenum, all of the small intestine, caecum and appendix, transverse colon, sigmoid colon and rectum. In these sections of the gut, there is a clear boundary between the gut and the surrounding tissue. These parts of the tract have a mesentery. Retroperitoneal parts are covered with adventitia. They blend into the surrounding tissue and are fixed in position. For example, the retroperitoneal section of the duodenum usually passes through the transpyloric plane. These include the esophagus, pylorus of the stomach, distal duodenum, ascending colon, descending colon and anal canal. In addition, the oral cavity has adventitia.
== Uses == R/S-LA and RLA are widely available as over-the-counter nutritional supplements in the United States in the form of capsules, tablets, and aqueous liquids, and have been marketed as antioxidants and pertaining to cellular glucose utilization for metabolic disorders and type 2 diabetes. Although the body can synthesize LA, it can also be absorbed from the diet. Dietary supplementation in doses from 200–600 mg is likely to provide up to 1000 times the amount available from a regular diet. Gastrointestinal absorption is variable and decreases with the use of food. It is therefore recommended that dietary LA be taken 30–60 minutes before or at least 120 minutes after a meal. Maximum blood levels of LA are achieved 30–60 minutes after dietary supplementation, and it is thought to be largely metabolized in the liver. In Germany, LA is approved as a drug for the treatment of diabetic neuropathy since 1966 and is available as a non-prescription pharmaceutical.
Some closely linked chordates and hemichordates, but that idea is now rejected. Combining such analyses with data from a small set of ribosome RNA genes eliminated some older ideas, but opened up the possibility that tunicates (urochordates) are "basal deuterostomes", surviving members of the group from which echinoderms, hemichordates and chordates evolved. Some researchers believe that, within the chordates, craniates are most closely related to cephalochordates, but there are also reasons for regarding tunicates (urochordates) as craniates' closest relatives. Since early chordates have left a poor fossil record, attempts have been made to calculate the key dates in their evolution by molecular phylogenetics techniques—by analyzing biochemical differences, mainly in RNA. One such study suggested that deuterostomes arose before 900 million years ago and the earliest chordates around 896 million years ago. However, molecular estimates of dates often disagree with each other and with the fossil record, and their assumption that the molecular clock runs at a known constant rate has been challenged. Traditionally, Cephalochordata and Craniata were grouped into the proposed clade "Euchordata", which would have been the sister group to Tunicata/Urochordata. More recently, Cephalochordata has been thought of as a sister group to the "Olfactores", which includes the craniates and tunicates. The matter is not yet settled.
=== Cocaine === Cocaine, in contrast to marijuana or alcohol, is a powerful stimulant. Upon entering the bloodstream, it rapidly reaches the brain within minutes, causing a significant surge in dopamine levels. The effects of cocaine are intense but short-lived, typically lasting about 30 minutes. The primary method of administration is through nasal insufflation (snorting), although it can also be smoked in crystal rock form. The rapid increase in dopamine levels during use contributes to a pronounced and challenging comedown, often prompting individuals to seek higher doses in subsequent use to achieve the same effects as experienced previously. This pattern can contribute to the development of addiction. The effects of cocaine use include increased energy and euphoria, accompanied by potential negative effects such as paranoia, rapid heart rate, and anxiety, among others.
Sources: en.wikipedia.org
Obesity: Across different cultures and ancestries, between 30% and 80% of women with PMOS are overweight or obese. There is marked weight gain between adolescence and adulthood, compared to those without PMOS. Dyslipidemia: disorders of fat (lipid) metabolism such as cholesterol and triglycerides: in PMOS, levels of low-density lipoprotein cholesterol are often high, while high-density cholesterol levels are low. Metabolic dysfunction–associated steatotic liver disease (MASLD; a chronic liver disease), particularly if androgen levels are high High blood pressure Metabolic syndrome, which occurs in about 40% of women with PMOS Cardiovascular disease: women with PMOS have about a two-fold increased risk of strokes and coronary heart disease compared to women without PMOS who have similar BMI. PMOS increases the risk of pregnancy complications, such as gestational diabetes, high blood pressure, low blood sugar levels, and pre-eclampsia. Miscarriages are more likely, and when a baby is delivered, they are more likely to require admission to the neonatal intensive care unit. PMOS is associated with mental health-related conditions including depression, anxiety, bipolar disorder, and obsessive–compulsive disorder. Those with PMOS often report reduced quality of life due to excess body weight, and to a lesser extent due to hirsutism, infertility and menstrual cycles. In regions where infertility or hirsutism are stigmatised, the impact on mental health is more severe. Body image can be negatively affected and PMOS increases the risk of eating disorders, such as binge eating.
==== Heritage Guernsey ==== On 2 July Essendon unveiled their Heritage Guernsey. It feature all the names of past premiership players in the background along with the name and signature of club legend John Colman on the breast. Under the signature include the traditional Essendon Football Club motto 'suaviter in modo, fortiter in re' which dates back to the 1870s and translates as 'gentle in manner, resolute in deed.' The most notable change to the guernsey was the removal of the black background to comply with AFL rules requiring each club to provide a clash guernsey. The new Heritage guernsey made its debut during the Round 15 game between St Kilda and Essendon. This marked the end of a 114-year-long tradition as the first time the Essendon Football Club would play an AFL/VFL game without wearing its famous black and red stripe guernsey.
Major medical organizations hold varying positions on the prophylactic efficacy of the elective circumcision of minors in developed countries. Literature on the matter is polarized, with the cost-benefit analysis highly dependent on the kinds and frequencies of health problems in the population under discussion and how circumcision affects them. The World Health Organization (WHO), UNAIDS, and American medical organizations take the position that its prophylactic health benefits outweigh the risks, while European, Australian, and New Zealand medical organizations generally hold that its medical benefits are insufficient to justify it. Advocates of circumcision recommend performing it during the neonatal period when it is less expensive and has a lower risk of complications. The American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Centers for Disease Control and Prevention have said that circumcision's potential benefits outweigh the risks. In 2010, the World Health Organization said:
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.